UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data
In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $329.00 to $355.00.
In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”
Regeneron Pharmaceuticals closed on Friday at $305.65.
Latest Ratings for REGN
|Nov 2014||Bank of America||Maintains||Buy|
|Nov 2014||Brean Capital||Maintains||Buy|
|Nov 2014||Argus Research||Maintains||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.